Strategic partnerships Arbutus Biopharma is actively engaging in collaborations with major players, including a recent global settlement and potential up to 2.5 billion in payments related to Moderna and Genevant. This indicates a receptive environment for co-development, licensing, and milestone-based deals that could expand access to imdusiran and AB-101.

Late-stage focus The company is a clinical-stage biopharma concentrating on infectious disease and chronic hepatitis B, with ongoing data presentations at major conferences. This presents opportunities to position products for clinical trial enablement services, investigator-sponsored trials, and strategic data-driven outreach to academic medical centers.

Key leadership New CEO appointment and active board changes signal a strategic shift and growth-oriented governance. This opens doors for executive-level outreach, alliance discussions, and potential joint ventures aligned with a refreshed corporate vision.

Market visibility Active participation in industry events such as AASLD and EASL, along with SAB formation, demonstrates ongoing product validation and scientific credibility. Sales opportunities exist in access partnerships, advisory roles, and early engagement with KHOs and biopharma strategists evaluating cHBV therapies.

Financial positioning With a revenue range of 10–25 million and a strategic focus on scalable, potentially milestone-driven programs, there is room to propose financing partnerships, translational funding, or collaboration models that de-risk development and accelerate potential approvals for imdusiran and AB-101.